Outcomes based on induction regimens in pediatric kidney transplantation: a NAPRTCS and PHIS collaborative study
Pediatric Nephrology · 2023
DOI: 10.1007/s00467-023-05955-5 ↗At a glance
Journal article in Pediatric Nephrology, 2023. Written by Daniella Levy Erez and 5 co-authors. Institution: Children's Hospital of Philadelphia, Philadelphia, PA, USA. levy.erez.daniella@gmail.com. Major MEDLINE topics: Kidney Transplantation, Health Information Systems. Cited 3 times so far (Crossref); 25 references.
Abstract (original language)
BACKGROUND: Induction agent used at the time of kidney transplant is often based upon center practice and recipient characteristics. We evaluated outcomes across induction therapies among children enrolled in the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) transplant registry with data in the Pediatric Health Information System (PHIS). METHODS: This is a retrospective study of merged data from NAPRTCS and PHIS. Participants were grouped by induction agent: interleukin-2 receptor blocker (IL-2 RB), anti-thymocyte/anti-lymphocyte globulin (ATG/ALG), and alemtuzumab. Outcomes assessed included 1-, 3-, and 5-year allograft function and survival, rejection, viral infections, malignancy, and death. RESULTS: A total of 830 children transplanted between 2010 and 2019. At 1 year post-transplant, the alemtuzumab group had higher median eGFR (86 ml/min/1.73 m2) compared to IL-2 RB and ATG/ALG (79 and 75 ml/min/1.73 m2, respectively; P < 0.001); at 3 and 5 years, there was no difference. Adjusted eGFR over time was similar across all induction agents. Rejection rates were lower among the alemtuzumab group vs. IL-2RB and ATG (13.9% vs. 27.3% and 24.6%, respectively; P = 0.006). Adjusted ATG/ALG and alemtuzumab had higher hazard ratio for time to graft failure compared to IL-2 RB (HR 2.48 and HR 2.11, respectively; P < 0.05). Incidence of malignancy, mortality, and time to first viral infection was similar. CONCLUSION: Although rejection and allograft loss rates were distinct, the incidences of viral infection and malignancy were comparable across induction agents. By 3 years post-transplant, there was no difference in eGFR. A higher resolution version of the Graphical abstract is available as Supplementary information.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Children's Hospital of Philadelphia, Philadelphia, PA, USA. levy.erez.daniella@gmail.com.
- Schneider Children's Medical Center, Petach Tiqva, Israel. levy.erez.daniella@gmail.com.
- Cedars-Sinai Medical Center, Los Angeles, CA, USA.
- Boston Children's Hospital, Boston, MA, USA.
- Children's Hospital Association, Lenexa, KS, USA.
Cite
APA
Erez, D. L., Pizzo, H., Rodig, N., Richardson, T., Somers, M., & NAPRTCS investigators (2023). Outcomes based on induction regimens in pediatric kidney transplantation: a NAPRTCS and PHIS collaborative study. Pediatric Nephrology. https://doi.org/10.1007/s00467-023-05955-5
Vancouver
Erez DL, Pizzo H, Rodig N, Richardson T, Somers M, NAPRTCS investigators. Outcomes based on induction regimens in pediatric kidney transplantation: a NAPRTCS and PHIS collaborative study. Pediatric Nephrology. 2023. doi:10.1007/s00467-023-05955-5
BibTeX
@article{Erez2023,
author = {Erez, Daniella Levy and Pizzo, Helen and Rodig, Nancy and Richardson, Troy and Somers, Michael and NAPRTCS investigators, NAPRTCS investigators},
title = {Outcomes based on induction regimens in pediatric kidney transplantation: a NAPRTCS and PHIS collaborative study},
journal = {Pediatric Nephrology},
year = {2023},
doi = {10.1007/s00467-023-05955-5}
}
EUVIMED